MILDRED ONIME: Open Payments
NPI 1609282391 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,488 in 68 payments from 29 companies in 2025. Trend: 2023 $340 · 2024 $632 · 2025 $2,488
Food & beverage: $1,488Long term medical supply or device loan: $798Education: $203
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 12 | $896 |
| Incyte Corporation | 4 | $170 |
| Janssen Biotech, Inc. | 5 | $169 |
| Stemline Therapeutics Inc. | 3 | $145 |
| Lilly USA, LLC | 5 | $134 |
| Daiichi Sankyo Inc. | 4 | $127 |
| Gilead Sciences, Inc. | 1 | $93 |
| Celgene Corporation | 2 | $67 |
| PharmaEssentia USA Corporation | 2 | $65 |
| E.R. Squibb & Sons, L.L.C. | 2 | $57 |
Products named: KISQALI, ELZONRIS, RYBREVANT, Enhertu, BESREMI, OPDIVO, MONOFERRIC, VERZENIO.
Industry payments across TX — which companies pay providers there.
